Holen Sie sich die Stockscreener-App
2.89
0.00%
0.00
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA) - The Globe and Mail
Sana Biotechnology, Inc. (SANA) Investor Outlook: A Biotech Player with a 171.89% Upside Potential - directorstalkinterviews.com
SANA: IND and phase I/II trial for diabetes therapy and first-in-human CAR T data expected within 12 months - TradingView
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com Australia
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com Canada
Sana Biotechnology | 8-K: Current report - Moomoo
SANA Q2 2026 Earnings: Steeper Loss of -$0.22 Per Share Misses Estimates; Shares Slide 10.4%Core Business Growth - dars.gov.et
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - The Conway Daily Sun
SANA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Cost PressuresAnnual Earnings Summary - dars.gov.et
Sana Biotechnology to Present at September 2026 Investor Conferences - The Manila Times
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer PATEL DHAVALKUMAR DHIRAJLALmoomoo - Moomoo
Sana (SANA) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison; Post-Report: Shares Finish 4.55% Higher in the Latest SessionRevenue Report - vinanet.vn
Sana (SANA) Outlook: Moves 4.55% Higher to $3.91 in Latest Trading; the Supplied Trading Band Runs From $3.71 to $4.11 in the Latest SessionOvervalued Signals - dars.gov.et
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention - Kalkine Media
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - Sahm
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2%Time to Sell? - MarketBeat
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely? - Moomoo
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9%Still a Buy? - MarketBeat
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses? - Sahm
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - The Globe and Mail
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - MarketBeat
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - MarketBeat
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget
Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - MarketBeat
Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net
Sana: Q2 Earnings Snapshot - KVUE
Sana Biotechnology | 8-K: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Moomoo
BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Sana Biotechnology (SANA) Advances 2.56% as Shares Approach Key Resistance at $3.79Fibonacci Extension - dars.gov.et
Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK
Sana Biotechnology faces earnings test as CAR-T program advances - Investing.com
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):